ProShare Advisors’s Forte Biosciences FBRX Stock Holding History

ProShare Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27	Closed	-$109K	–	1638
2019 Q1	$109K	Buy	+27	New	+$104K	﹤0.01%	1563
2018 Q4	–	Sell	-28	Closed	-$161K	–	1619
2018 Q3	$161K	Sell	28 -1	-3%	-$3.81K	﹤0.01%	1627
2018 Q2	$100K	Sell	29 -1	-3%	-$3.66K	﹤0.01%	1709
2018 Q1	$136K	Sell	30 -6	-17%	-$27.8K	﹤0.01%	1601
2017 Q4	$136K	Buy	+36	New	+$144K	﹤0.01%	1705

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ProShare Advisors's FBRX Position: Q2 2019 in Review

ProShare Advisors sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 27 shares — an estimated $109K sold.

ProShare Advisors first reported a position in FBRX in Q4 2017 and held it in 5 quarters. The position peaked at $161K in Q3 2018. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

ProShare Advisors reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
ProShare Advisors sold 27 Forte Biosciences shares in Q2 2019, an estimated $109K.
ProShare Advisors first reported a position in Forte Biosciences in Q4 2017 and held it in 5 quarters.
ProShare Advisors's Forte Biosciences position peaked at $161K in Q3 2018.
74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on ProShare Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.